Padcev (Enfortumab Vedotin) is a Nectin-4-directed antibody and microtubule inhibitor conjugate used for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
Dosage: The recommended dose of Padcev is 1.25 mg/kg (up to a maximum of 125 mg for patients ≥100 kg) should be administered as an intravenous infusion over 30 minutes on Days 1, 8 and 15 of a 28-day cycle until the disease is progressive or unacceptable toxicity occurs.
Side Effects: The most commonly reported enfortumab vedotin side effects include:
- Peripheral neuropathy
- Decreased appetite
- Dry eye
- Pruritus and dry skin
Warnings and Precautions:
- Closely monitor patients with enfortumab vedotin-ejfv 30 mg for blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia.
- Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction of enfortumab vedotin when peripheral neuropathy occurs.
- Padcev can cause fetal harm when administered to a pregnant woman. Females of reproductive potential are advised to use effective contraception during treatment with padcev 30 mg and for 2 months after the last dose.
- Male patients with female partners of reproductive potential are advised to use effective contraception while on treatment with enfortumab vedotin and for four months following the last dose.
- Due to the risk for serious adverse events in a breastfed child, lactating women are advised not to breastfeed while on treatment with padcev 20 mg and for at least 21 days after the last dose.